

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/079796 A1

(51) International Patent Classification:

C07K 19/00 (2006.01) **A61P 31/14** (2006.01)
A61K 39/00 (2006.01) **A61P 37/04** (2006.01)
A61K 39/155 (2006.01) **C07K 14/135** (2006.01)
A61K 39/295 (2006.01) **C12N 15/45** (2006.01)
A61K 9/107 (2006.01) **C12N 15/62** (2006.01)
A61K 9/127 (2006.01)

(21) International Application Number:

PCT/CA2008/002277

(22) International Filing Date:

23 December 2008 (23.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/016,524 24 December 2007 (24.12.2007) US
61/056,206 27 May 2008 (27.05.2008) US

(71) Applicants (for all designated States except US): **ID BIOMEDICAL CORPORATION OF QUEBEC** [CA/CA]; 525 Cartier Boulevard West, Laval, Québec H7V 3S8 (CA). **GlaxoSmithKline Biologicals s.a.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAUDOUX, Jean-Pierre** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). **BLAIS, Normand** [CA/CA]; 525 Cartier Ouest, Laval, Québec, H6V 3S8 (CA). **RHEAULT, Patrick** [CA/CA]; 525 Cartier Ouest, Laval, Québec H7V 3S8 (CA). **RUELLE, Jean-Louis** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agents: **D'ORIO, Hélène** et al.; Gowling Lafleur Henderson LLP, 1 Place Ville Marie, 37th Floor, Montréal, Québec H3B 3P4 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(54) Title: RECOMBINANT RSV ANTIGENS

FIG. 1A



(57) Abstract: This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.